Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Medicina (Kaunas) ; 59(4)2023 Mar 26.
Artículo en Inglés | MEDLINE | ID: covidwho-2296980

RESUMEN

Introduction: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The majority of infected patients develop the clinical picture of a respiratory disease, although some may develop various complications, such as arterial or venous thrombosis. The clinical case presented herein is a rare example of sequential development and combination of acute myocardial infarction, subclavian vein thrombosis (Paget Schroetter syndrome), and pulmonary embolism in the same patient after COVID-19. Case presentation: A 57-year-old man with a 10-day history of a SARS-CoV-2 infection was hospitalized with a clinical, electrocardiographic, and laboratory constellation of an acute inferior-lateral myocardial infarction. He was treated invasively and had one stent implanted. Three days after implantation, the patient developed shortness of breath and palpitation on the background of a swollen and painful right hand. The signs of acute right-sided heart strain observed on the electrocardiogram and the elevated D-dimer levels strongly suggested pulmonary embolism. A Doppler ultrasound and invasive evaluation demonstrated thrombosis of the right subclavian vein. The patient was administered pharmacomechanical and systemic thrombolysis and heparin infusion. Revascularization was achieved 24 h later via successful balloon dilatation of the occluded vessel. Conclusion: Thrombotic complications of COVID-19 can develop in a significant proportion of patients. Concomitant manifestation of these complications in the same patient is extremely rare, presenting at the same time, quite a therapeutic challenge to clinicians due to the need for invasive techniques and simultaneous administration of dual antiaggregant therapy combined with an anticoagulant treatment. Such a combined treatment increases the hemorrhagic risk and requires a serious accumulation of data for the purpose of a long-term antithrombotic prophylaxis in patients with such pathology.


Asunto(s)
COVID-19 , Infarto del Miocardio , Embolia Pulmonar , Enfermedades Torácicas , Trombosis Venosa Profunda de la Extremidad Superior , Trombosis de la Vena , Masculino , Humanos , Persona de Mediana Edad , COVID-19/complicaciones , Vena Subclavia , SARS-CoV-2 , Trombosis de la Vena/etiología , Trombosis de la Vena/tratamiento farmacológico , Embolia Pulmonar/complicaciones , Infarto del Miocardio/complicaciones , Trombosis Venosa Profunda de la Extremidad Superior/complicaciones , Trombosis Venosa Profunda de la Extremidad Superior/diagnóstico , Trombosis Venosa Profunda de la Extremidad Superior/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA